GSK Ireland on behalf of ViiV Healthcare is pleased to announce that eligible people living with Human Immunodeficiency Virus (HIV) in Ireland now have access to Vocabria (cabotegravir long-acting injection) developed by ViiV Healthcare in combination with Rekambys (rilpivirine long-acting injection) developed by Janssen Sciences Ireland UC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Vocabria and Rekambys is indicated for the treatment of HIV type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL), on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse transcriptase inhibitor (NNRTI) and integrase inhibitor (INI) class.1
This marks the first time that people living with HIV in Ireland can access a complete, long-acting regimen once every two-months. This could reduce the number of days receiving treatment from 365 to 6 per year, when on the continuation injection phase of treatment.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
